"An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients with Heart Failure with Preserved Ejection Fraction (HFpEF) DELIVER - Dapagliflozin Evaluation to Improve the LIVEs of Patients with PReserved Ejection Fraction Heart Failure "

drug protocol number
D169CC00001
drug sponsor
AstraZeneca
drug study
Dapagliflozin
drug trial site
KKUH
drug status
Completed
drug phase